Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that Radionuclide imaging may be employed in the assessment of a variety of conditions 
associated with primary coronary artery disease. Some of these conditions include: 
 
    1. Assessment of the functional and prognostic importance of angina, chest pain, or angina equivalent 
symptoms. 
    2. Diagnostic evaluation of patients with chest pain and uninterpretable or equivocal ECG/EKG changes 
occurring naturally or caused by drugs, bundle branch block, or left ventricular hypertrophy. 
    3. Risk assessment of re-evaluation of disease in patients who are asymptomatic or have stable symptoms, 
with known atherosclerotic heart disease on catheterization or SPECT perfusion imaging, who have not had a 
revascularization procedure within the past two years or greater than 2 years since last imaging study. 
    4. Detection of coronary artery disease in patients, without chest pain syndrome, with new-onset of 
diagnosed heart failure or left ventricular systolic dysfunction. 
    5. Evaluation of ischemic versus non-ischemic cardiomyopathy when cardiac catheterization/coronary 
angiography is not planned. 
    6. Evaluation of myocardial perfusion viability or function before and more than or equal to 5 years after 
coronary artery bypass surgery or greater than or equal to 2 years after percutaneous perfusion procedures, 
unless new clinical signs or symptoms necessitate reevaluation. 
    7. Quantification and surveillance of myocardial infarction and prognostication in patient with infarction.  
    8. Preoperative assessment for non-cardiac surgery, when used to determine risk for surgery or perioperative 
management in: 
        Patients with minor or intermediate clinical risk predictors and poor functional capacity. 
        Patients with intermediate or high likelihood of coronary heart disease, or patients with poor functional 
capacity undergoing high risk non-cardiac surgery. 
    The ACC/AHA 2014 Guidelines on Perioperative Cardiovascular Evaluation and Care for Non-Cardiac 
Surgery1; provides the following information regarding categorization of surgical risk. They include: 
        high risk/intermediate risk surgery: aortic and peripheral vascular surgery; intraperitoneal and 
intrathoracic surgery, carotid endarterectomy, head and neck surgery, orthopedic surgery and prostate surgery; 
        low risk surgery: endoscopic procedure, superficial surgery, cataract surgery, breast surgery, ambulatory 
surgery; 
        The Guidelines establish poor functional capacity as less than 4 METS; 
        Utilization of these tests is based on the presence of multiple risk factors, the level of functional capacity, 
the risk of surgery proposed, and the likelihood that the results of the cardiac testing would change the 
management. 
    9. Evaluation of ventricular function in patients with non-ischemic myocardial disease. 
    10. Evaluation of patients in whom an accurate measure of the ejection fraction is needed to make a 
determination of whether to implant a defibrillator or biventricular pacemaker. 
    11. Evaluation of patient receiving chemotherapeutic drugs which are potentially cardiotoxic (e.g., 
Adriamycin, Herceptin). 
 
First pass studies will be considered medically necessary only when information sought is immediately relevant 
to the management of the patient's clinical condition and has not been previously obtained or likely to be 
obtained from other planned tests such as echocardiography or equilibrium gated blood pool studies. First pass 
studies may be indicated for the assessment and identification of shunts and are more likely to be done in 
suspected congenital events. It is noted that occasionally first pass studies and gated blood pool studies may be 
additive when RVEF is needed on the same day. 
 
Infarct Avid Scintigraphy is indicated in patients in whom it is not possible to make a definitive diagnosis of 
myocardial infarction by ECG/EKG or enzyme testing. 
 
Patient selection should be based on clinical grounds: 
 
    Patients with a high pretest probability of disease are not usually candidates for a study for diagnostic 
purposes, though the size and reversibility of a defect and its functional consequences may be required for 
clinical decision-making. 
    Patients with a moderate probability of disease benefit the most from the study when the diagnosis is in 
question. 
    Selection of tests should be made within the context of other tests, scheduled and previously performed so 
that the anticipated information obtained is unique and not redundant. 
    Redundant testing where multiple tests are done revealing the same information is not medically necessary 
and should be appropriately denied if reviewed. 
 
You can find this information in Medicare's Local Coverage Determination (LCD): Cardiovascular Nuclear 
Medicine (L35083). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com.